IQVIA

Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO

Retrieved on: 
Wednesday, December 6, 2023
Medical Devices, Health, Clinical Trials, Research, Science, Optical, Ophthalmology, OCT, Retina, Diabetic retinopathy, IQVIA, Patient, Prognosis, MD, Trial of the century, Doctor of Philosophy, Eyemo

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. (“IQVIA”) for eyeMO (Patient Based Ophthalmology Suite), a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.

Key Points: 
  • Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. (“IQVIA”) for eyeMO (Patient Based Ophthalmology Suite), a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.
  • This agreement is for a specific clinical study to be funded by Chugai Pharmaceutical Co., Ltd., and IQVIA will support this clinical study as a coordination management agency and pay for the loan of eyeMO to the Company.
  • Ryo Kubota, MD, PhD, Chairman, President, and CEO of Kubota Vision Inc., stated, “eyeMO is a state-of-the-art retinal monitoring device that aims to improve patient prognosis through promotion of home care in the field of ophthalmology.
  • *1 Optical Coherence Tomography (OCT) is a non-invasive tool that uses light waves to take cross-section pictures of the retina.

IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year

Retrieved on: 
Wednesday, November 29, 2023
Technology, Biotechnology, Online Privacy, Health, Pharmaceutical, Professional Services, Medical Devices, Digital Marketing, Advertising, General Health, Data Analytics, Communications, Health Technology, Clinical Trials, Editorial, GM, NYSE, Trailblazer, Social responsibility, IQVIA, Patient, IQV, XR, Advertising agency

IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.

Key Points: 
  • IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.
  • IQVIA Digital Enablement’s mission is to power exceptional brand experiences.
  • This includes IQVIA’s Audience Identity Manager® XR technology that helps marketers connect with HCPs,” says Anna Stashower, CEO and Publisher of PM360.
  • “We are proud to be recognized by PM360 Trailblazer for our achievements in delivering innovative customer-first solutions, so every customer touchpoint is personalized and leads to better health outcomes,” said Dave Escalante, VP and GM, IQVIA Digital Enablement.

Apollo Intelligence Names Susan Young as Chief Financial Officer (CFO)

Retrieved on: 
Wednesday, November 29, 2023
Software, General Health, Professional Services, Internet, Data Management, Technology, Other Communications, Other Professional Services, Marketing, Advertising, Communications, Health, Consulting, Young, CFO, Xerox, KKR, Culture, MarVista Entertainment, Intelligence, Clarkson University, Kodak, MBA, Software as a service, Growth, Syracuse University, Life, PlayOn, Management, Apollo, IQVIA

Apollo Intelligence (Apollo), a leading provider of real-time data and insights to the healthcare and life science industries, has named Susan J.

Key Points: 
  • Apollo Intelligence (Apollo), a leading provider of real-time data and insights to the healthcare and life science industries, has named Susan J.
  • Young as its Chief Financial Officer (CFO).
  • Young has significant international experience, including posts in Europe and management of teams and entities in the UK, Canada, Mexico, China, Singapore, and India.
  • Apollo welcomes Young and looks to her financial leadership to help drive growth and client impact in 2024.

IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023

Retrieved on: 
Tuesday, November 21, 2023
Software, Research, Pharmaceutical, Data Management, Technology, Security, Health Technology, Online Privacy, Clinical Trials, Science, Biotechnology, Health, Webcast, Information Holdings Inc., IQVIA, NYSE, Conference, IQV, Cryptocurrency, Broadcasting

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Retrieved on: 
Friday, November 17, 2023
FDA, Pharmaceutical, Health, Medicine, Vomiting, Digoxin, Osteoporosis, Woman, Urine, Antares, NYSE, Bone disease, Calcium, Spine, Prednisone, Constipation, Allergy, History, IQVIA, Patient, Arthralgia, Medication, TEVA, Fracture, Muscle weakness, System, Blood, Tongue, Vitamin, Bone tumor, Nausea, Kidney, Pain, Swelling, Osteosarcoma, Skin, Rat, TASE, Injection, Face, Blood pressure, Generic drug, Dietary supplement, Pharmaceutical industry, Vaccine, Birth control, Injection moulding, Medical imaging, Poultry farming, Phosphorus, Teriparatide, Teva

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.

Key Points: 
  • Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
  • Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • Teva’s generic equivalent of Forteo® (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device.
  • Teriparatide injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.

IQVIA Announces Upsizing of its Allocation of New Term B Loans

Retrieved on: 
Friday, November 17, 2023
Data Analytics, Health, Data Management, Health Technology, Professional Services, Technology, Online Privacy, Security, Hilltop Holdings Inc., IQVIA, NYSE, IQV, TLB, Security (finance)

IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand.

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand.
  • The proceeds from the New Term Loan B, together with the proceeds from the Borrower’s offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), are expected to be used to repay the outstanding Euro-denominated term B loan (“TLB”) due in March 2024, the U.S.-denominated TLB due in January 2025 and the U.S.-denominated TLB due in June 2025 under the Borrower’s senior secured credit facilities, and to pay fees and expenses related to the Borrower’s Notes offering and the Borrower’s credit agreement amendment in respect of the New Term Loan B.
  • In connection with the allocation of the New Term Loan B, the Company entered into a cross-currency swap agreement which will effectively convert the New Term Loan B, upon the closing of such facility, into a euro-denominated borrowing at prevailing euro interest rates to hedge exposure to USD-denominated indebtedness created by the New Term Loan B.
  • The effective net borrowing rate to the Company will be 4.9015%, inclusive of the yield on the New Term Loan B and the beneficial impact of the cross-currency swap.

IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes

Retrieved on: 
Wednesday, November 15, 2023
Online Privacy, Technology, Medical Devices, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Data Management, Sale, NYSE, IQVIA, IQV, Debtor, Credit, Person, SEC Rule 144A, Regulation, Security (finance), Note

IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), which was upsized due to strong demand.

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), which was upsized due to strong demand.
  • The proceeds from the Notes offering, together with the proceeds from the New Term Loan B, are expected to be used to repay certain of the outstanding term loans under the Borrower’s senior secured credit facilities due in 2024 and in 2025, and to pay fees and expenses related to the Issuer’s Notes offering and the Borrower’s Credit Agreement Amendment.
  • The Notes will mature on February 1, 2029, unless earlier repurchased or redeemed in accordance with their terms.
  • Any offer of the Notes will be made only by means of a private offering memorandum.

Toshiba Global Commerce Solutions Appoints Todd Regelsberger as Chief Financial Officer

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Other Retail, Consumer Electronics, Technology, Other Technology, Retail, Software, Networks, Internet, Mobile, Wireless, Hardware, Accounting, Carrier Global, Thermo Fisher Scientific, CFO, Treasury, Investment, History, Multimedia, Ecosystem, Toshiba, Kodak, Bausch & Lomb, Ferdinand Regelsberger, Growth, Development, Face, Management, Online shopping, IQVIA

Toshiba Global Commerce Solutions announced that Todd Regelsberger joined the company as its new Chief Financial Officer (CFO), effective November 6, 2023.

Key Points: 
  • Toshiba Global Commerce Solutions announced that Todd Regelsberger joined the company as its new Chief Financial Officer (CFO), effective November 6, 2023.
  • Regelsberger comes to Toshiba with more than 25 years of financial experience leading financial teams across controllership, internal auditing, treasury, financial planning and analysis, manufacturing, and international operations.
  • View the full release here: https://www.businesswire.com/news/home/20231114483428/en/
    Todd Regelsberger joins Toshiba Global Commerce Solutions as CFO and brings over 25 years of experience leading financial teams across multiple high-profile organizations worldwide.
  • His extensive history with international organizations and leadership will contribute to Toshiba Global Commerce Solutions' continued growth as a global leader in retail technology.

IQVIA Announces Offering of Senior Secured Notes

Retrieved on: 
Tuesday, November 14, 2023
Research, Technology, Health Technology, Professional Services, Software, Biotechnology, Data Analytics, Health, Data Management, Science, Sale, NYSE, IQVIA, IQV, Debtor, Credit, Person, SEC Rule 144A, Regulation, Failure, Security (finance), Note

IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”).

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”).
  • The proceeds from the Notes offering, together with the proceeds from the New Term Loan B, are expected to be used to repay certain of the outstanding term loans under the Borrower’s senior secured credit facilities and to pay fees and expenses related to the Issuer’s Notes offering and the Borrower’s Credit Agreement Amendment.
  • The consummation of the Notes offering is subject to market and other customary conditions.
  • The Credit Agreement Amendment and the New Term Loan B are not conditioned on the consummation of the Notes offering, and the Notes offering is not conditioned on the consummation of the Credit Agreement Amendment or the incurrence of the New Term Loan B.

Patient Engagement Solutions Market Worth $41.8 Billion | MarketsandMarkets

Retrieved on: 
Friday, December 15, 2023
Cloud, Acquisition, Conditional sentence, Athenahealth, Investment, Patient, Oracle Corporation, Growth, Hospital, Diabetes, RWE, Market development, Cardiovascular disease, Health, Roe, MEA, MEDITECH, EHR, Research, Tablet, Obesity, McKesson Corporation, ADH, Epic Systems, Francisco Partners, Software, Pulse, Medical device, Nursing, Health care, Pharmaceutical industry, IQVIA, Telehealth, Merck, Humana, Merative

In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.

Key Points: 
  • In 2023, the software segment is estimated to account for the largest share of the patient engagement solutions market.
  • In terms of delivery mode, the patient engagement solutions market is categorized into on-premise and cloud-based/web-based modes.
  • Patient Engagement Solutions Market Dynamics:
    Key Market Players of Patient Engagement Solutions Industry:
    Prominent players in patient engagement solutions market are McKesson Corporation (US), Veradigm (US), Oracle Corporation (US), Merative (US), Epic Systems Corporation (US), Orion Health (New Zealand), GetWellNetwork (US), athenahealth (US), Oneview Healthcare (Ireland), MEDITECH (US), IQVIA (US), Get Real Health (US), Cognizant (US), Harris Healthcare (US), Kareo (US), CureMD Healthcare (US), eClinicalWorks (US), and Lincor Solutions (US), AdvancedMD (US), Luma Health Inc. (US), WellStack(US), Vivify Health (US), Medhost (US), MEDISYSINC (US), and  Patient point LLC (US).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the patient engagement solutions market.